Loading
Batea Oncology makes GlioHook, an implant placed in the space left after brain tumour surgery to gather leftover cancer cells in one place and make them more sensitive to radiotherapy. It is in a first small study in people with suspected high-grade glioma.
Batea Oncology S.L., of Santiago de Compostela, A Coruna, Spain, develops GlioHook, which it describes as a class III medical device for glioblastoma. Implanted to cover the resection margins after surgery, it is designed to concentrate residual tumour cells in a controlled location, turning an infiltrative disease into a focal one, and to sensitise those cells to radiotherapy. A prospective, multicentre, single-arm pilot investigation (NCT07725640) plans to enrol 15 patients with suspected high-grade glioma at sites in Barcelona, Madrid and Santiago de Compostela, with Apices Soluciones listed as collaborator. Its first registered cancer trial, NCT07725640, was posted on ClinicalTrials.gov in July 2026.
Shares Radiosensitisers, Glioma & glioblastoma.
Shares Brain and spinal cord tumours (all types), Glioma & glioblastoma.
Shares Brain and spinal cord tumours (all types), Glioma & glioblastoma.
Shares Brain and spinal cord tumours (all types), Glioma & glioblastoma.
Shares Brain and spinal cord tumours (all types), Glioma & glioblastoma.
Shares Brain and spinal cord tumours (all types), Glioma & glioblastoma.
Shares Brain and spinal cord tumours (all types), Glioma & glioblastoma.
Shares Brain and spinal cord tumours (all types), Glioma & glioblastoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/